Abstract
Evidence-based clinical practice guidelines recommend the use of warfarin for stroke prevention in most patients with atrial fibrillation (AF) who do not have risk factors for hemorrhagic complications, or other contraindications, irrespective of age. The past couple of years have seen an increased awareness and scrutiny addressing the dilemma of warfarin prescribing with particular emphasis on risk factors that increase the propensity for overanticoagulation and bleeding. This coupled with some promising news of personalized medicine using pharmacogenomics for warfarin dosing is the focus of this commentary.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Medical Directors Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
